Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2022-04-21 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司股东大会工作条例（2022年4修订）
Governance Information Classification · 100% confidence The document is titled as the "Shareholders' Meeting Work Rules" of a company, detailing the procedures, powers, and regulations governing the shareholders' meetings. It includes chapters on the general principles, convening of meetings, proposals and notifications, meeting conduct, voting and resolutions, and supplementary provisions. The content is a governance document outlining internal rules and procedures related to shareholder meetings rather than a report of financial results, announcements, or other filings. It does not contain financial statements, audit opinions, voting results, or announcements of meetings but rather the rules and governance framework for conducting shareholder meetings. Therefore, it fits best under Governance Information (CGR).
2022-04-21 Chinese
金宇生物技术股份有限公司对外投资管理办法（2022年4月修订）
Governance Information Classification · 95% confidence The document is titled '金宇生物技术股份有限公司 对外投资管理办法' which translates to 'Jinyu Biotechnology Co., Ltd. External Investment Management Measures'. It outlines the company's internal policies and procedures for managing external investments, including approval processes, responsibilities, and oversight mechanisms. There is no indication that this is a financial report, earnings release, or regulatory filing. It is a governance-related document detailing internal rules and management practices related to investments. The document length is 3428 characters, which is relatively short but contains substantive policy content rather than an announcement or brief notice. Therefore, the most appropriate classification is Governance Information (CGR).
2022-04-21 Chinese
金宇生物技术股份有限公司关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policy by the company 金宇生物技术股份有限公司. It details the reasons for the change, the new accounting standards being adopted, the impact on financial statements, and includes opinions from independent directors and the supervisory board. The document does not contain actual financial statements or comprehensive financial data but rather explains the policy change and its implications. It is not a full annual or interim report, nor is it a certification or a brief announcement of a report publication. This type of document fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2022-04-21 Chinese
金宇生物技术股份有限公司关于召开2021年度暨2022年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about a scheduled investor meeting to discuss the 2021 annual results and 2022 first quarter results. It provides details about the meeting time, location, format, and participation instructions. It does not contain actual financial statements or detailed financial analysis but rather serves as a notice for an upcoming earnings explanation session. The document length is short (1591 characters) and it is clearly an announcement of an event rather than the event transcript or report itself. Therefore, it fits best as a Call Transcript (CT) announcement or an Investor Presentation (IP) announcement. However, since it is specifically about an earnings explanation meeting (业绩说明会), which is typically a form of investor presentation focusing on financial results and strategy, the best classification is Investor Presentation (IP).
2022-04-21 Chinese
金宇生物技术股份有限公司章程（2022年4月修订）
Governance Information Classification · 100% confidence The document is the Articles of Association (章程) of 金宇生物技术股份有限公司, which is a detailed corporate governance document outlining the company's organizational structure, shareholder rights, board of directors, management, financial accounting, profit distribution, auditing, and procedures for shareholder meetings. It includes detailed provisions on shares, shareholder meetings, voting, board and management roles, and other governance matters. This type of document is a governance information report detailing the company's internal rules, board structure, and governance practices. It is not an announcement, nor a financial report, nor a meeting presentation or transcript. Therefore, the appropriate classification is Governance Information (CGR). The document length and content confirm it is a full governance document, not a brief announcement or summary.
2022-04-21 Chinese
金宇生物技术股份有限公司关于2021年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company's board regarding the 2021 annual asset impairment provision. It details the amounts and types of impairment losses recognized, including credit impairment losses, inventory write-downs, fixed asset impairment, and goodwill impairment. The document includes explanations of accounting standards applied and the impact on the company's financial results for 2021. It is not a full annual report but a specific announcement about impairment provisions approved by the board. The document length is 2729 characters, which is relatively short and focused on a specific accounting matter rather than comprehensive financial statements or management discussion. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about accounting estimates and provisions, not a full audit report or annual report.
2022-04-21 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.